HKD18.42
0.11% yesterday
Hong Kong, Jul 09, 10:08 am CET
ISIN
CNE100000FN7
Symbol
1099
Index
Sector
Industry

Sinopharm Group Target price 2025 - Analyst rating & recommendation

Sinopharm Group Classifications & Recommendation:

Buy
71%
Hold
24%
Sell
5%

Sinopharm Group Price Target

Target Price HKD22.64
Price HKD18.42
Potential
Number of Estimates 17
17 Analysts have issued a price target Sinopharm Group 2026 . The average Sinopharm Group target price is HKD22.64. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 21 analysts: 15 Analysts recommend Sinopharm Group to buy, 5 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Sinopharm Group stock has an average upside potential 2026 of . Most analysts recommend the Sinopharm Group stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Billion HKD 638.98 666.91
2.02% 4.28%
EBITDA Margin 3.35% 3.49%
16.88% 4.03%
Net Margin 1.21% 1.34%
20.53% 11.10%

19 Analysts have issued a sales forecast Sinopharm Group 2025 . The average Sinopharm Group sales estimate is

HKD667b
Unlock
. This is
4.28% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
HKD715b 11.88%
Unlock
, the lowest is
HKD619b 3.10%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 HKD639b 2.02%
2025
HKD667b 4.28%
Unlock
2026
HKD696b 4.30%
Unlock
2027
HKD732b 5.21%
Unlock
2028
HKD692b 5.46%
Unlock
2029
HKD713b 3.01%
Unlock

16 Analysts have issued an Sinopharm Group EBITDA forecast 2025. The average Sinopharm Group EBITDA estimate is

HKD23.3b
Unlock
. This is
5.41% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
HKD29.9b 21.46%
Unlock
, the lowest is
HKD18.4b 25.04%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 HKD21.4b 18.56%
2025
HKD23.3b 8.56%
Unlock
2026
HKD24.3b 4.32%
Unlock
2027
HKD25.9b 6.47%
Unlock
2028
HKD19.9b 23.21%
Unlock
2029
HKD20.5b 3.01%
Unlock

EBITDA Margin

2024 3.35% 16.88%
2025
3.49% 4.03%
Unlock
2026
3.49% 0.00%
Unlock
2027
3.53% 1.15%
Unlock
2028
2.87% 18.70%
Unlock
2029
2.87% 0.00%
Unlock

19 Sinopharm Group Analysts have issued a net profit forecast 2025. The average Sinopharm Group net profit estimate is

HKD9.0b
Unlock
. This is
16.14% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
HKD10.6b 37.24%
Unlock
, the lowest is
HKD7.5b 3.18%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 HKD7.7b 22.14%
2025
HKD9.0b 16.14%
Unlock
2026
HKD9.5b 6.30%
Unlock
2027
HKD9.9b 4.28%
Unlock
2028
HKD6.6b 34.04%
Unlock
2029
HKD6.8b 3.14%
Unlock

Net Margin

2024 1.21% 20.53%
2025
1.34% 11.10%
Unlock
2026
1.37% 2.24%
Unlock
2027
1.36% 0.73%
Unlock
2028
0.95% 30.15%
Unlock
2029
0.95% 0.00%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share HKD 2.47 2.87
22.08% 16.19%
P/E 6.42
EV/Sales 0.12

19 Analysts have issued a Sinopharm Group forecast for earnings per share. The average Sinopharm Group EPS is

HKD2.87
Unlock
. This is
16.19% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
HKD3.39 37.25%
Unlock
, the lowest is
HKD2.39 3.24%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 HKD2.47 22.08%
2025
HKD2.87 16.19%
Unlock
2026
HKD3.05 6.27%
Unlock
2027
HKD3.18 4.26%
Unlock
2028
HKD2.10 33.96%
Unlock
2029
HKD2.16 2.86%
Unlock

P/E ratio

Current 7.47 9.52%
2025
6.42 14.01%
Unlock
2026
6.04 5.92%
Unlock
2027
5.80 3.97%
Unlock
2028
8.79 51.55%
Unlock
2029
8.52 3.07%
Unlock

Based on analysts' sales estimates for 2025, the Sinopharm Group stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.13 35.00%
2025
0.12 5.54%
Unlock
2026
0.12 4.07%
Unlock
2027
0.11 5.01%
Unlock
2028
0.12 5.81%
Unlock
2029
0.11 2.96%
Unlock

P/S ratio

Current 0.09 8.97%
2025
0.09 4.10%
Unlock
2026
0.08 4.16%
Unlock
2027
0.08 4.94%
Unlock
2028
0.08 5.83%
Unlock
2029
0.08 2.99%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today